Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOT first-line therapy for elderly mantle-cell lymphoma
2009-015909-39Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab, bendamustine and dexamethasone in mantle cell lymphoma (MCL), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Complete or major clinical-hematological response rate, Safety profile of DOT combination therapy and 1 more. Started Nov 2009; status: completed.
02
Drugs
ofatumumabbendamustinedexamethasone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2009-015909-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015909-39.